Formation, characterization, and fate of inhaled drug nanoparticles

Advanced Drug Delivery Reviews

Volumn 63, Issue 6, 2011, Pages 441-455

  Zhang, Jian ^a   Wu, Libo ^a   Chan, Hak Kim ^b   Watanabe, Wiwik ^a  

^a MAP Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Clearance; Formation; In vitro; In vivo; Inhalation; Nanoparticle; Performance

Indexed keywords

CLEARANCE; FORMATION; IN-VITRO; IN-VIVO; INHALATION; PERFORMANCE;

DRUG DELIVERY; POLYMERS;

NANOPARTICLES;

AERONEB; ATROPINE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; CYCLOSPORIN A; FLUTICASONE PROPIONATE; GOLD; IRIDIUM; ITRACONAZOLE; NANOPARTICLE; NICOTINE; POLITEF; POLYSTYRENE; SALBUTAMOL SULFATE; SILICON DIOXIDE; SUMATRIPTAN SUCCINATE; SURFACTANT; TECHNETIUM 99M; TERBUTALINE SULFATE; TITANIUM DIOXIDE; UNCLASSIFIED DRUG;

ANTISOLVENT METHOD; ASPERGILLOSIS; ASTHMA; CHEMICAL REACTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONDENSATION AEROSOL GENERATION; CRYOGENIC SOLVENT EVAPORATION; CYSTIC FIBROSIS; DEHYDRATION; DIARRHEA; DISSOLUTION; DRUG ADMINISTRATION ROUTE; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG TARGETING; DRUG UPTAKE; ENZYME ACTIVITY; EVAPORATION; EVAPORATIVE PRECIPITATION INTO AQUEOUS SOLUTION; FIRST PASS EFFECT; GAMMA SCINTIGRAPHY; HIGH GRAVITY CONTROLLED PRECIPITATION; HIGH PRESSURE HOMOGENIZATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHALATIONAL DRUG ADMINISTRATION; INTERMETHOD COMPARISON; JET MILLING METHOD; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; MICROEMULSION METHOD; MICROFLUIDICS; MUCOCILIARY CLEARANCE; NEBULIZER; NONHUMAN; PATIENT COMPLIANCE; PEAK INSPIRATORY FLOW; POWDER INHALER; PRIORITY JOURNAL; PROCESS TECHNOLOGY; RAPID EXPANSION OF SUPERCRITICAL SOLUTION; REVIEW; SINGLE DRUG DOSE; SOLVENT EVAPORATION METHOD; SUPERCRITICAL FLUID EXTRACTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOP DOWN METHOD; WET MILLING METHOD;

ADMINISTRATION, INHALATION; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 79957692320     PISSN: 0169409X     EISSN: 0169409X     Source Type: Journal    
DOI: 10.1016/j.addr.2010.11.002     Document Type: Review

References (184)

1. Georgakilas V., Gournis D., Tzitzios V., Pasquato L., Guldi D.M., Prato M. Decorating carbon nanotubes with metal or semiconductor nanoparticles. J. Mater. Chem. 2007, 17:2679-2694.
2. Boutonnet M., Lögdberg S., Elm Svensson E. Recent developments in the application of nanoparticles prepared from w/o microemulsions in heterogeneous catalysis. Curr. Opin. Colloid Interface Sci. 2008, 13:270-286.
3. De M., Ghosh P.S., Rotello V.M. Applications of nanoparticles in biology. Adv. Mater. 2008, 20:4225-4241.
4. Gupta R.B., Kompella U.B. Nanoparticle Technology for Drug Delivery 2006, Taylor & Francis Group.
5. Joachim C. To be nano or not to be nano?. Nat. Mater. 2005, 4:107-109.
6. Royal Society and Royal Academy of Engineering Nanoscience and Nanotechnologies: Opportunities and Uncertainties 2004.
7. Riehemann K., Schneider Stefan W., Luger Thomas A., Godin B., Ferrari M., Fuchs H. Nanomedicine - challenge and perspectives. Angew. Chem. Int. Ed. 2009, 48:872-897.
8. Date A.A., Patravale V.B. Current strategies for engineering drug nanoparticles. Curr. Opin. Colloid Interface Sci. 2004, 9:222-235.
9. des Rieux A., Fievez V., Garinot M., Schneider Y.-J., Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 2006, 116:1-27.
10. Shi Y., Porter W., Merdan T., Li L.C. Recent advances in intravenous delivery of poorly water-soluble compounds. Expert Opin. Drug Deliv. 2009, 6:1261-1282.
11. Cevc G., Vierl U. Nanotechnology and the transdermal route: a state of the art review and critical appraisal. J. Control. Release 2010, 141:277-299.
12. Wadhwa S., Paliwal R., Paliwal S.R., Vyas S.P. Nanocarriers in ocular drug delivery: an update review. Curr. Pharm. Des. 2009, 15:2724-2750.
13. Ragab D.M., Rohani S. Particle engineering strategies via crystallization for pulmonary drug delivery. Org. Process Res. Dev. 2009, 13:1215-1223.
14. Rogueda P.G., Traini D. The nanoscale in pulmonary delivery. Part 2: Formulation platforms. Expert Opin. Drug Deliv. 2007, 4:607-620.
15. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
16. Pathak Y., Thassu D. Drug delivery nanoparticles formulation and characterization 2007, Informa Healthcare.
17. Thassu D., Deleers M., Pathak Y. Nanoparticulate Drug Delivery Systems 2007, Informa Healthcare.
18. Muller R.H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 2001, 47:3-19.
19. Merisko-Liversidge E.M., Liversidge G.G. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 2008, 36:43-48.
20. Thayer A.M. Finding solutions. Chem. Eng. News 2010, 88:13-18.
21. Oberdorster G., Oberdorster E., Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 2005, 113:823-839.
22. Oberdörster G., Ferin J., Lehnert B.E. Correlation between particle size, in vivo particle persistence, and lung injury. Environ. Health Perspect. 1994, 102:173-179.
23. Zheng J.Y., Bosch H.W. Sterile filtration of NanoCrystal™ drug formulations. Drug Dev. Ind. Pharm. 1997, 23:1087-1093.
24. Mansour H.M., Rhee Y.S., Wu X. Nanomedicine in pulmonary delivery. Int. J. Nanomedicine 2009, 4:299-319.
25. Sung J.C., Pulliam B.L., Edwards D.A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007, 25:563-570.
26. Labiris N.R., Dolovich M.B. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 2003, 56:588-599.
27. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007, 6:67-74.
28. Yang W., Johnston K.P., Williams R.O. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur. J. Pharm. Biopharm. 2010, 75:33-41.
29. Gill S., Lobenberg R., Ku T., Azarmi S., Roa W., Prenner E.J. Nanoparticles: characteristics, mechanisms of action, and toxicity in pulmonary drug delivery - a review. J. Biomed. Nanotechnol. 2007, 3:107-119.
30. Gonda I. Systemic delivery of drugs to humans via inhalation. J. Aerosol Med. 2006, 19:47-53.
31. Labiris N.R., Dolovich M.B. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 2003, 56:600-612.
32. Yeo L.Y., Friend J.R., McIntosh M.P., Meeusen E.N., Morton D.A. Ultrasonic nebulization platforms for pulmonary drug delivery. Expert Opin. Drug Deliv. 2010, 7:663-679.
33. Daniher D.I., Zhu J. Dry powder platform for pulmonary drug delivery. Particuology 2008, 6:225-238.
34. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 2004, 3:785-796.
35. Van Eerdenbrugh B., Van den Mooter G., Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int. J. Pharm. 2008, 364:64-75.
36. Tam J.M., Engstrom J.D., Ferrer D., III R.O.W., Johnston K.P. Templated open flocs of anisotropic particles for pulmonary delivery with pressurized metered dose inhalers. J. Pharm. Sci. 2010, 99:3150-3165.
37. Ostrander K.D., Bosch H.W., Bondaza D.M., Parry-Billings M. Potential delivery advantages of spray-dried nanocrystal™ colloidal budesonide with the clickhaler ® Respiratory Drug Delivery VII 2000, 447-450.
38. Mykhaylova V., Urbanetz N.A. New alternative techniques to produce flowable powder for dry powder inhaler. Drug Delivery to the Lungs XVI 2005, 33-36.
39. Chiang P.-C., Alsup J., Lai Y., Hu Y., Heyde B., Tung D. Evaluation of aerosol delivery of nanosuspension for pre-clinical pulmonary drug delivery. Nanoscale Res. Lett. 2009, 4:254-261.
40. El-Gendy N., Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm. Res. 2009, 26:1752-1763.
41. El-Gendy N., Berkland C. Combination nanoparticle agglomerates of fluticasone propionate and albuterol sulphate. Respiratory Drug Delivery 2010, Orlando, FL 2010, 819-824.
42. Jacobs C., Müller R.H. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 2002, 19:189-194.
43. Patravale V.B., Date A.A., Kulkarni R.M. Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharmacol. 2004, 56:827-840.
44. Ponchel G., Montisci M.-J., Dembri A., Durrer C., Duchêne D. Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract. Eur. J. Pharm. Biopharm. 1997, 44:25-31.
45. Ghirardelli R., Bonasoro F., Porta C., Cremaschi D. Identification of particular epithelial areas and cells that transport polypeptide-coated nanoparticles in the nasal respiratory mucosa of the rabbit. Biochim. Biophys. Acta 1999, 1416:39-47.
46. Bailey M.M., Berkland C.J. Nanoparticle formulations in pulmonary drug delivery. Med. Res. Rev. 2009, 29:196-212.
47. Keck C.M., Müller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 2006, 62:3-16.
48. Wiedmann T.S., DeCastro L., Wood R.W. Nebulization of NanoCrystals™: production of a respirable solid-in-liquid-in-air colloidal dispersion. Pharm. Res. 1997, 14:112-116.
49. Ostrander K.D., Bosch H.W., Bondanza D.M. An in-vitro assessment of a nanocrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur. J. Pharm. Biopharm. 1999, 48:207-215.
50. Ali H.S.M., York P., Blagden N. Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. Int. J. Pharm. 2009, 375:107-113.
51. Chow A.H.L., Tong H.H.Y., Chattopadhyay P., Shekunov B.Y. Particle engineering for pulmonary drug delivery. Pharm. Res. 2007, 24:411-437.
52. Rasenack N., Mueller B.W. Micron-size drug particles: common and novel micronization techniques. Pharm. Dev. Technol. 2004, 9:1-13.
53. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm. Res. 2008, 25:999-1022.
54. Weers J.G., Tarara T.E., Clark A.R. Design of fine particles for pulmonary drug delivery. Expert Opin. Drug Deliv. 2007, 4:297-313.
55. Rogers T.L., Nelsen A.C., Hu J., Brown J.N., Sarkari M., Young T.J., Johnston K.P., Williams R.O. A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid. Eur. J. Pharm. Biopharm. 2002, 54:271-280.
56. Foster T.P., Leatherman M.W. Powder characteristics of proteins spray-dried from different spray-dryers. Drug Dev. Ind. Pharm. 1995, 21:1705-1723.
57. Barron M.K., Young T.J., Johnston K.P., Williams R.O. Investigation of processing parameters of spray freezing into liquid to prepare polyethylene glycol polymeric particles for drug delivery. AAPS PharmSciTech 2003, 4:E12.
58. Chen X., Young T.J., Sarkari M., Williams R.O., Johnston K.P. Preparation of cyclosporine a nanoparticles by evaporative precipitation into aqueous solution. Int. J. Pharm. 2002, 242:3-14.
59. Dickinson P.A., Howells S.W., Kellaway I.W. Novel nanoparticles for pulmonary drug administration. J. Drug Target. 2001, 9:295-302.
60. Kawashima Y., York P. Drug delivery applications of supercritical fluid technology. Adv. Drug Deliv. Rev. 2008, 60:297-298.
61. Zhao H., Shao L., Chen J.-F. High-gravity process intensification technology and application. Chem. Eng. J. 2010, 156:588-593.
62. Dhumal R.S., Biradar S.V., Paradkar A.R., York P. Particle engineering using sonocrystallization: salbutamol sulphate for pulmonary delivery. Int. J. Pharm. 2009, 368:129-137.
63. Panagiotou T., Fisher R.J. Form nanoparticles via controlled crystallization. Chem. Eng. Prog. 2008, 104:33-39.
64. Reddy L.H., Sharma R.K., Chuttani K., Mishra A.K., Murthy R.R. Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies. AAPS J. 2004, 6:e23.
65. Kesisoglou F., Panmai S., Wu Y. Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 2007, 59:631-644.
66. Deng Z., Xu S., Li S. Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications. Int. J. Pharm. 2008, 351:236-243.
67. Chan H.-K., Chew N.Y.K. Novel alternative methods for the delivery of drugs for the treatment of asthma. Adv. Drug Deliv. Rev. 2003, 55:793-805.
68. Chougule M.B., Padhi B.K., Jinturkar K.A., Misra A. Development of dry powder inhalers. Recent Pat. Drug Deliv. Formul. 2007, 1:11-21.
69. Türk M., Lietzow R. Stabilized nanoparticles of phytosterol by rapid expansion from supercritical solution into aqueous solution. AAPS PharmSciTech 2004, 5:36-45.
70. Young T.J., Mawson S., Johnston K.P., Henriksen I.B., Pace G.W., Mishra A.K. Rapid expansion from supercritical to aqueous solution to produce submicron suspensions of water-insoluble drugs. Biotechnol. Prog. 2000, 16:402-407.
71. Badens E., Majerik V., Horváth G., Szokonya L., Bosc N., Teillaud E., Charbit G. Comparison of solid dispersions produced by supercritical antisolvent and spray-freezing technologies. Int. J. Pharm. 2009, 377:25-34.
72. Chiang P.-C., Hu Y., Blom J., Thompson D. Evaluating the suitability of using rat models for preclinical efficacy and side effects with inhaled corticosteroids nanosuspension formulations. Nanoscale Res. Lett. 2010, 5:1010-1019.
73. Burgess D.J. Injectable dispersed systems - formulation, processing, and performance 2005, Taylor & Francis Group.
74. Kraft W.K., Steiger B., Beussink D., Quiring J.N., Fitzgerald N., Greenberg H.E., Waldman S.A. The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J. Clin. Pharmacol. 2004, 44:67-72.
75. Shrewsbury S.B., Bosco A.P., Uster P.S. Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. Int. J. Pharm. 2009, 365:12-17.
76. Keller M., Jauernig J., Lintz F.-C., Knoch M. Nebulizer nanosuspensions: important device and formulation interactions. Respiratory Drug Delivery 2002, 197-206.
77. Luangkhot N., Jauernig J., Balcke A., Lintz F.-C., Liening-Ewert R., Stangl R., Keller M. Characterisation of salbutamol solution compared to budesonide suspensions consisting of submicron and micrometer particles in the PARI LC STAR® and a new PARI electronic nebuliser (e-flow). Drug Delivery to the Lungs 12, 2000 2000, 14-17.
78. Bhavna, Ahmad F., Khar R., Sultana S., Bhatnagar A. Techniques to develop and characterize nanosized formulation for salbutamol sulfate. J. Mater. Sci. Mater. Med. 2009, 20:71-76.
79. James J., Crean B., Davies M., Toon R., Jinks P., Roberts C.J. The surface characterisation and comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers. Int. J. Pharm. 2008, 361:209-221.
80. Jinks P. Preparation and utility of sub-micron lactose: a novel excipient for HFA pMDI suspensions formulations. Drug Delivery to the Lungs XIV 2003, 199-202.
81. Okuyama K., Wuled Lenggoro I. Preparation of nanoparticles via spray route. Chem. Eng. Sci. 2003, 58:537-547.
82. Thybo P., Hovgaard L., Lindeløv J., Brask A., Andersen S. Scaling up the spray drying process from pilot to production scale using an atomized droplet size criterion. Pharm. Res. 2008, 25:1610-1620.
83. Freitas C., Müller R.H. Spray-drying of solid lipid nanoparticles (SLNTM). Eur. J. Pharm. Biopharm. 1998, 46:145-151.
84. Mehnert W., Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47:165-196.
85. Mizoe T., Ozeki T., Okada H. Preparation of drug nanoparticle-containing microparticles using a 4-fluid nozzle spray drier for oral, pulmonary, and injection dosage forms. J. Control. Release 2007, 122:10-15.
86. Yang Z.-Y., Le Y., Hu T.-T., Shen Z., Chen J.-F., Yun J. Production of ultrafine sumatriptan succinate particles for pulmonary delivery. Pharm. Res. 2008, 25:2012-2018.
87. Engstrom J., Lai E., Ludher B., Chen B., Milner T., Williams R., Kitto G., Johnston K. Formation of stable submicron protein particles by thin film freezing. Pharm. Res. 2008, 25:1334-1346.
88. Yang W., Tam J., Miller D.A., Zhou J., McConville J.T., Johnston K.P., Williams R.O. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int. J. Pharm. 2008, 361:177-188.
89. Rogers T.L., Hu J., Yu Z., Johnston K.P., Williams R.O. A novel particle engineering technology: spray-freezing into liquid. Int. J. Pharm. 2002, 242:93-100.
90. Vaughn J.M., McConville J.T., Burgess D., Peters J.I., Johnston K.P., Talbert R.L., Williams R.O. Single dose and multiple dose studies of itraconazole nanoparticles. Eur. J. Pharm. Biopharm. 2006, 63:95-102.
91. Engstrom J., Tam J., Miller M., Williams R.O., Johnston K. Templated open flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose inhalers. Pharm. Res. 2009, 26:101-117.
92. Overhoff K.A., Engstrom J.D., Chen B., Scherzer B.D., Milner T.E., Johnston K.P., Williams R.O. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 2007, 65:57-67.
93. Sinswat P., Overhoff K.A., McConville J.T., Johnston K.P., Williams R.O. Nebulization of nanoparticulate amorphous or crystalline tacrolimus - single-dose pharmacokinetics study in mice. Eur. J. Pharm. Biopharm. 2008, 69:1057-1066.
94. Cook R.O., Pannu R.K., Kellaway I.W. Novel sustained release microspheres for pulmonary drug delivery. J. Control. Release 2005, 104:79-90.
95. Gupta R., Hindle M., Byron P.R., Cox K.A., McRae D.D. Investigation of a novel condensation aerosol generator: solute and solvent effects. Aerosol Sci. Technol. 2003, 37:672-681.
96. Li X., Blondino F.E., Hindle M., Soine W.H., Byron P.R. Stability and characterization of perphenazine aerosols generated using the capillary aerosol generator. Int. J. Pharm. 2005, 303:113-124.
97. Hong J.N., Hindle M., Byron P.R. Control of particle size by coagulation of novel condensation aerosols in reservoir chambers. J. Aerosol Med. 2002, 15:359-368.
98. Simis K., Lei M., Lu A.T., Sharma K.C.V., Hale R.L., Timmons R., Cassella J. Nicotine aerosol generation from thermally reversible zinc halide complexes using the staccato® system. Drug Dev. Ind. Pharm. 2008, 34:936-942.
99. Martín A., Cocero M.J. Micronization processes with supercritical fluids: fundamentals and mechanisms. Adv. Drug Deliv. Rev. 2008, 60:339-350.
100. Pasquali I., Bettini R., Giordano F. Supercritical fluid technologies: an innovative approach for manipulating the solid-state of pharmaceuticals. Adv. Drug Deliv. Rev. 2008, 60:399-410.
101. Charpentier P.A., Jia M., Lucky R.A. Study of the RESS process for producing beclomethasone-17, 21-dipropionate particles suitable for pulmonary delivery. AAPS PharmSciTech 2008, 9:39-46.
102. Dalvi S.V., Dave R.N. Controlling particle size of a poorly water-soluble drug using ultrasound and stabilizers in antisolvent precipitation. Ind. Eng. Chem. Res. 2009, 48:7581-7593.
103. Yang H.-J., Chu G.-W., Zhang J.-W., Shen Z.-G., Chen J.-F. Micromixing efficiency in a rotating packed bed: experiments and simulation. Ind. Eng. Chem. Res. 2005, 44:7730-7737.
104. Tung H.-H., Paul E.L., Midler M., McCauley J.A. Crystallization of Organic Compounds 2009, Wiley & Sons, Inc.
105. Matteucci M.E., Hotze M.A., Johnston K.P., Williams R.O. Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir 2006, 22:8951-8959.
106. Tam J.M., McConville J.T., Williams R.O., Johnston K.P. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J. Pharm. Sci. 2008, 97:4915-4933.
107. Chen J.F., Zhou M.Y., Shao L., Wang Y.Y., Yun J., Chew N.Y., Chan H.K. Feasibility of preparing nanodrugs by high-gravity reactive precipitation. Int. J. Pharm. 2004, 269:267-274.
108. Ali R., Jain G.K., Iqbal Z., Talegaonkar S., Pandit P., Sule S., Malhotra G., Khar R.K., Bhatnagar A., Ahmad F.J. Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote. Nanomedicine 2009, 5:55-63.
109. Hu T.-T., Wang J.-X., Shen Z.-G., Chen J.-F. Engineering of drug nanoparticles by HGCP for pharmaceutical applications. Particuology 2008, 6:239-251.
110. Hu T., Chiou H., Chan H.-K., Chen J.-F., Yun J. Preparation of inhalable salbutamol sulphate using reactive high gravity controlled precipitation. J. Pharm. Sci. 2008, 97:944-949.
111. Zhang J.-Y., Shen Z.-G., Zhong J., Hu T.-T., Chen J.-F., Ma Z.-Q., Yun J. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. Int. J. Pharm. 2006, 323:153-160.
112. Okamoto H., Danjo K. Application of supercritical fluid to preparation of powders of high-molecular weight drugs for inhalation. Adv. Drug Deliv. Rev. 2008, 60:433-446.
113. Reverchon E., Adami R. Nanomaterials and supercritical fluids. J. Supercrit. Fluids 2006, 37:1-22.
114. Pasquali I., Bettini R. Are pharmaceutics really going supercritical?. Int. J. Pharm. 2008, 364:176-187.
115. Foster N., Mammucari R., Dehghani F., Barrett A., Bezanehtak K., Coen E., Combes G., Meure L., Ng A., Regtop H.L., Tandya A. Processing pharmaceutical compounds using dense gas technology. Ind. Eng. Chem. Res. 2003, 42:6476-6493.
116. Richardson C.H., Matas M., Hosker H., Mukherjee R., Wong I., Chrystyn H. Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization. Pharm. Res. 2007, 24:2008-2017.
117. Tenorio A., Gordillo M.D., Pereyra C., de la Ossa E.J.M. Controlled submicro particle formation of ampicillin by supercritical antisolvent precipitation. J. Supercrit. Fluids 2007, 40:308-316.
118. Zhao H., Wang J.X., Wang Q.A., Chen J.F., Yun J. Controlled liquid antisolvent precipitation of hydrophobic pharmaceutical nanoparticles in a microchannel reactor. Ind. Eng. Chem. Res. 2007, 46:8229-8235.
119. Newman S.P., Wilding I.R., Hirst P.H. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products?. Int. J. Pharm. 2000, 208:49-60.
120. Clark A.R., Gonda I., Newhouse M.T. Towards meaningful laboratory tests for evaluation of pharmaceutical aerosols. J. Aerosol Med. 1998, 11(Suppl 1):S1-7.
121. Heng D., Cutler D.J., Chan H.K., Yun J., Raper J.A. What is a suitable dissolution method for drug nanoparticles?. Pharm. Res. 2008, 25:1696-1701.
122. Son Y.-J., McConville J.T. Development of a standardized dissolution test method for inhaled pharmaceutical formulations. Int. J. Pharm. 2009, 382:15-22.
123. Davies N.M., Feddah M.R. A novel method for assessing dissolution of aerosol inhaler products. Int. J. Pharm. 2003, 255:175-187.
124. Gray V.A., Hickey A.J., Balmer P., Davies N.M., Dunbar C., Foster T.S., Olsson B.L., Sakagami M., Shah V.P., Smurthwaite M.J., Veranth J.M., Zaidi K. The inhalation ad hoc advisory panel for the USP performance tests of inhalation dosage forms. Phamacopeial. Forum 2008, 34:1068-1074.
125. Hickey A.J. Pharmaceutical Inhalation Aerosol Technology 2004, Marcel Dekker, Inc. 2nd ed.
126. USP <601> aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers. U.S. Pharmacopeia 2009, 32.
127. Merkus H.G. Particle Size Measurements: Fundamentals, Practice, Quality 2008, Springer.
128. Newman S.P., Wilding I.R. Gamma scintigraphy: an in vivo technique for assessing the equivalence of inhaled products. Int. J. Pharm. 1998, 170:1-9.
129. Newman S.P., Wilding I.R. Imaging techniques for assessing drug delivery in man. Pharm. Sci. Technol. Today 1999, 2:181-189.
130. Snell N.J.C., Ganderton D. Assessing lung deposition of inhaled medications: consensus statement from a workshop of the British association for lung research, held at the Institute of Biology, London, U.K. On 17 April 1998. Respir. Med. 1999, 93:123-133.
131. Newman S.P., Pitcairn G.R., Hirst P.H., Rankin L. Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs. Adv. Drug Deliv. Rev. 2003, 55:851-867.
132. Videira M.A., Botelho M.F., Santos A.C., Gouveia L.F., de Lima J.J., Almeida A.J. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J. Drug Target. 2002, 10:607-613.
133. Bondesson E., Bengtsson T., Borgström L., Nilsson L.-E., Norrgren K., Trofast E., Wollmer P. Planar gamma scintigraphy - points to consider when quantifying pulmonary dry powder aerosol deposition. Int. J. Pharm. 2003, 258:227-240.
134. Eberl S., Chan H.K., Daviskas E. Spect imaging for radioaerosol deposition and clearance studies. J. Aerosol Med. 2006, 19:8-20.
135. Chan H.K., Eberl S., Glover W. Radiolabelling of pharmaceutical aerosols and gamma scintigraphic imaging for lung deposition. Encyclopaedia of Pharmaceutical Technology 2006, 3094-3107. Informa Healthcare, New York. J. Swarbrick (Ed.).
136. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug Deliv. Rev. 2006, 58:1030-1060.
137. Cryan S.-A., Sivadas N., Garcia-Contreras L. In vivo animal models for drug delivery across the lung mucosal barrier. Adv. Drug Deliv. Rev. 2007, 59:1133-1151.
138. McConville J., Overhoff K., Sinswat P., Vaughn J., Frei B., Burgess D., Talbert R., Peters J., Johnston K., Williams R. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm. Res. 2006, 23:901-911.
139. Bosco A.P., Castillo M.C., Luangvala M.M. A novel submicron formulation of nebulized budesonide significantly improves the fine particle fraction of drug available for inhalation from various jet nebulizers compared to a marketed budesonide suspension. J. Allergy Clin. Immunol. 2009, 123:S156.
140. Bosco A., Armer T.A., Uster P.S. A submicron suspension of budesonide improves the mass of ICS delivered during early nebulization. Eur. Respir. J. 2006, 28:712s.
141. Dalby R.N., Byron P.R. Comparison of output particle size distributions from pressurized aerosols formulated as solutions or suspensions. Pharm. Res. 1988, 5:36-39.
142. Smyth H.D.C. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv. Drug Deliv. Rev. 2003, 55:807-828.
143. Alvarez C.A., Wiederhold N.P., McConville J.T., Peters J.I., Najvar L.K., Graybill J.R., Coalson J.J., Talbert R.L., Burgess D.S., Bocanegra R., Johnston K.P., Williams R.O. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J. Infect. 2007, 55:68-74.
144. Hoeben B.J., Burgess D.S., McConville J.T., Najvar L.K., Talbert R.L., Peters J.I., Wiederhold N.P., Frei B.L., Graybill J.R., Bocanegra R., Overhoff K.A., Sinswat P., Johnston K.P., Williams R.O. In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 2006, 50:1552-1554.
145. Yang W., Wiederhold N.P., Williams R.O. Drug delivery strategies for improved azole antifungal action. Expert Opin. Drug Deliv. 2008, 5:1199-1216.
146. Schmid O., Moller W., Semmler-Behnke M., Ferron G.A., Karg E., Lipka J., Schulz H., Kreyling W.G., Stoeger T. Dosimetry and toxicology of inhaled ultrafine particles. Biomarkers 2009, 14(Suppl 1):67-73.
147. Gehr P., Blank F., Rothen-Rutishauser B.M. Fate of inhaled particles after interaction with the lung surface. Paediatr. Respir. Rev. 2006, 7(Suppl 1):S73-75.
148. Kreyling W.G., Semmler-Behnke M., Moller W. Ultrafine particle-lung interactions: does size matter?. J. Aerosol Med. 2006, 19:74-83.
149. Nikula K.J., Avila K.J., Griffith W.C., Mauderly J.L. Lung tissue responses and sites of particle retention differ between rats and cynomolgus monkeys exposed chronically to diesel exhaust and coal dust. Fundam. Appl. Toxicol. 1997, 37:37-53.
150. Muhlfeld C., Rothen-Rutishauser B., Blank F., Vanhecke D., Ochs M., Gehr P. Interactions of nanoparticles with pulmonary structures and cellular responses. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 294:L817-829.
151. Palko H.A., Fung J.Y., Louie A.Y. Positron emission tomography: a novel technique for investigating the biodistribution and transport of nanoparticles. Inhal. Toxicol. 2010, 22:657-688.
152. Nemmar A., Hoet P.H.M., Vanquickenborne B., Dinsdale D., Thomeer M., Hoylaerts M.F., Vanbilloen H., Mortelmans L., Nemery B. Passage of inhaled particles into the blood circulation in humans. Circulation 2002, 105:411-414.
153. Brown J.S., Zeman K.L., Bennett W.D. Ultrafine particle deposition and clearance in the healthy and obstructed lung. Am. J. Respir. Crit. Care Med. 2002, 166:1240-1247.
154. Wiebert P., Sanchez-Crespo A., Seitz J., Falk R., Philipson K., Kreyling W.G., Moller W., Sommerer K., Larsson S., Svartengren M. Negligible clearance of ultrafine particles retained in healthy and affected human lungs. Eur. Respir. J. 2006, 28:286-290.
155. Muhlfeld C., Gehr P., Rothen-Rutishauser B. Translocation and cellular entering mechanisms of nanoparticles in the respiratory tract. Swiss Med. Wkly 2008, 138:387-391.
156. Green F.H.Y., Schurch S., Gehr P., Lee M.M. The role of surfactant in disease associated with particle exposure. Particle-Lung Interactions 2000, 533-576. Marcel Dekker, Inc., New York. P. Gehr, J. Heyder (Eds.).
157. Lay J.C., Stang M.R., Fisher P.E., Yankaskas J.R., Bennett W.D. Airway retention of materials of different solubility following local intrabronchial deposition in dogs. J. Aerosol Med. 2003, 16:153-166.
158. Edsbacker S., Wollmer P., Selroos O., Borgstroem L., Olsson B., Ingelf J. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?. Pulm. Pharmacol. Ther. 2008, 21:247-258.
159. Anderson S.D., Brannan J.D., Chan H.K. Use of aerosols for bronchial provocation testing in the laboratory: where we have been and where we are going. J. Aerosol Med. Deposition Clearance Eff. Lung 2002, 15:313-324.
160. Daviskas E., Anderson S.D., Gomes K., Briffa P., Cochrane B., Chan H.K., Young I.H., Rubin B.K. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005, 10:46-56.
161. Formoterol and budesonide inhaler, in. http://www.cipladoc.com/therapeutic/pdf_cipla/foracort_hfa%20_inhaler.pdf.
162. Camner P., Mossberg B. Airway mucus clearance and mucociliary transport. Aerosols in Medicine, Principles, Diagnosis and Therapy 1993, 247-260. Elsevier, Amsterdam. F. Moren, M.B. Dolovich, M.T. Newhouse, S.P. Newman (Eds.).
163. Daviskas E., Anderson S.D., Gonda I., Eberl S., Meikle S., Seale J.P., Bautovich G. Inhalation of hypertonic saline aerosol enhances mucociliary clearance in asthmatic and healthy subjects. Eur. Respir. J. 1996, 9:725-732.
164. Robinson M., Eberl S., Tomlinson C., Daviskas E., Regnis J.A., Bailey D.L., Torzillo P.J., Menache M., Bye P.T. Regional mucociliary clearance in patients with cystic fibrosis. J. Aerosol Med. 2000, 13:73-86.
165. Daviskas E., Anderson S.D., Eberl S., Chan H.K., Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 1999, 159:1843-1848.
166. Daviskas E., Anderson S.D., Eberl S., Chan H.K., Young I.H. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 2001, 119:414-421.
167. Daviskas E., Anderson S.D., Shaw J., Eberl S., Seale J.P., Yang I.A., Young I.H. Mucociliary clearance in patients with chronic asthma: effects of beta agonists. Respirology 2005, 10:426-435.
168. Regnis J.A., Robinson M., Bailey D.L., Cook P., Hooper P., Chan H.K., Gonda I., Bautovich G., Bye P.T. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am. J. Respir. Crit. Care Med. 1994, 150:66-71.
169. Roth C., Scheuch G., Stahlhofen W. Clearance of the human lungs for ultrafine particles. J. Aerosol Sci. 1993, 24:S95-S96.
170. Oberdörster G. Biokinetics and effects of nanoparticles. Nanotechnology - Toxicological Issues and environmental safety 2007, 15-51. Springer, Netherlands. P.P. Simeonova, N. Opopol, M.I. Luster (Eds.).
171. Geiser M., Kreyling W.G. Deposition and biokinetics of inhaled nanoparticles. Part. Fibre Toxicol. 2010, 7.
172. Videira M.A., Botelho M.F., Santos A.C., Gouveia L.F., de Lima J.J.P., Almeida A.J. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J. Drug Target. 2002, 10:607-613.
173. Yang W., Peters J.I., Williams R.O. Inhaled nanoparticles - a current review. Int. J. Pharm. 2008, 356:239-247.
174. Borm P., Klaessig F.C., Landry T.D., Moudgil B., Pauluhn J., Thomas K., Trottier R., Wood S. Research strategies for safety evaluation of nanomaterials, Part V: Role of dissolution in biological fate and effects of nanoscale particles. Toxicol. Sci. 2006, 90:23-32.
175. Madl A.K., Pinkerton K.E. Health effects of inhaled engineered and incidental nanoparticles. Crit. Rev. Toxicol. 2009, 39:629-658.
176. McWilliam A.S., Holt P.G., Gehr P. Dendritic cells as sentinels of immune surveillance in the airways. Particle-Lung Interactions 2000, 473-489. Marcel Dekker Inc., New York. P. Gehr, J. Heyder (Eds.).
177. Ferin J., Oberdorster G. Translocation of particles from pulmonary alveoli into the interstitium. J. Aerosol Med. Deposition Clearance Eff. Lung 1992, 5:179-187.
178. Oberdorster G., Stone V., Donaldson K. Toxicology of nanoparticles: a historical perspective. Nanotoxicology 2007, 1:2-25.
179. Unfried K., Albrecht C., Klotz L.O., Von Mikecz A., Grether-Beck S., Schins R.P.F. Cellular responses to nanoparticles: target structures and mechanisms. Nanotoxicology 2007, 1:52-71.
180. Heckel K., Kiefmann R., Dorger M., Stoeckelhuber M., Goetz A.E. Colloidal gold particles as a new in vivo marker of early acute lung injury. Am. J. Physiol. Lung C 2004, 287:L867-L878.
181. Semmler-Behnke M., Takenaka S., Fertsch S., Wenk A., Seitz J., Mayer P., Oberdorster G., Kreyling W.G. Efficient elimination of inhaled nanoparticles from the alveolar region: evidence for interstitial uptake and subsequent reentrainment onto airway epithelium. Environ. Health Perspect. 2007, 115:728-733.
182. Oberdorster G., Oberdorster E., Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Persp. 2005, 113:823-839.
183. Wang Z., Chen J.-F., Le Y., Shen Z.-G., Yun J. Preparation of ultrafine beclomethasone dipropionate drug powder by antisolvent precipitation. Ind. Eng. Chem. Res. 2007, 46:4839-4845.
184. Klingler C., Müller B.W., Steckel H. Insulin-micro- and nanoparticles for pulmonary delivery. Int. J. Pharm. 2009, 377:173-179.